The latent reservoir for HIV-1: How immunologic memory and clonal expansion contribute to HIV-1 persistence

Journal of Immunology

Volumn 197, Issue 2, 2016, Pages 407-417

  Murray, Alexandra J ^a   Kwon, Kyungyoon J ^a   Farber, Donna L ^b   Siliciano, Robert F ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLONE; HALF LIFE TIME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LATENT VIRUS INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS LATENCY; VIRUS REPLICATION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; VIROLOGY;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; VIRUS LATENCY;

EID: 84978128882     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1600343     Document Type: Review

References (210)

1. Lundgren, J. D., A. G. Babiker, F. Gordin, S. Emery, B. Grund, S. Sharma, A. Avihingsanon, D. A. Cooper, G. Fätkenheuer, J. M. Llibre, et al; INSIGHT START Study Group. 2015. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373: 795-807.
2. Danel, C., R. Moh, D. Gabillard, A. Badje, J. Le Carrou, T. Ouassa, E. Ouattara, A. Anzian, J. B. Ntakpé, et al.; TEMPRANO ANRS 12136 Study Group. 2015. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373: 808-822.
3. Gunthard, H. F., J. A. Aberg, J. J. Eron, J. F. Hoy, A. Telenti, C. A. Benson, D. M. Burger, P. Cahn, J. E. Gallant, M. J. Glesby, et al; International Antiviral Society-USA Panel. 2014. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312: 410-425.
4. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, et al. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337: 734-739.
5. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, et al; AIDS Clinical Trials Group 320 Study Team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337: 725-733.
6. Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
7. Davey, R. T., Jr., N. Bhat, C. Yoder, T. W. Chun, J. A. Metcalf, R. Dewar, V. Natarajan, R. A. Lempicki, J. W. Adelsberger, K. D. Miller, et al. 1999. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. USA 96: 15109-15114.
8. Rothenberger, M. K., B. F. Keele, S. W. Wietgrefe, C. V. Fletcher, G. J. Beilman, J. G. Chipman, A. Khoruts, J. D. Estes, J. Anderson, S. P. Callisto, et al. 2015. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc. Natl. Acad. Sci. USA 112: E1126-E1134.
9. Richman, D. D., D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, and R. J. Pomerantz. 2009. The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
10. Deeks, S. G., B. Autran, B. Berkhout, M. Benkirane, S. Cairns, N. Chomont, T. W. Chun, M. Churchill, M. Di Mascio, C. Katlama, et al; International AIDS Society Scientific Working Group on HIV Cure. 2012. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12: 607-614.
11. Chun, T. W., D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano. 1995. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat. Med. 1: 1284-1290.
12. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
13. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
14. Wong, J. K., M. Hezareh, H. F. Gunthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
15. Chun, T. W., L. Stuyver, S. B. Mizell, L. A. Ehler, J. A. Mican, M. Baseler, A. L. Lloyd, M. A. Nowak, and A. S. Fauci. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94: 13193-13197.
16. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5: 512-517.
17. + T cells. Nat. Med. 9: 727-728.
18. Crooks, A. M., R. Bateson, A. B. Cope, N. P. Dahl, M. K. Griggs, J. D. Kuruc, C. L. Gay, J. J. Eron, D. M. Margolis, R. J. Bosch, and N. M. Archin. 2015. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 212: 1361-1355.
19. Pierson, T., T. L. Hoffman, J. Blankson, D. Finzi, K. Chadwick, J. B. Margolick, C. Buck, J. D. Siliciano, R. W. Doms, and R. F. Siliciano. 2000. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J. Virol. 74: 7824-7833.
20. Brenchley, J. M., B. J. Hill, D. R. Ambrozak, D. A. Price, F. J. Guenaga, J. P. Casazza, J. Kuruppu, J. Yazdani, S. A. Migueles, M. Connors, et al. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J. Virol. 78: 1160-1168.
21. Chomont, N., M. El-Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab, G. Boucher, M. R. Boulassel, G. Ghattas, J. M. Brenchley, et al. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15: 893-900.
22. Josefsson, L., S. von Stockenstrom, N. R. Faria, E. Sinclair, P. Bacchetti, M. Killian, L. Epling, A. Tan, T. Ho, P. Lemey, et al. 2013. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc. Natl. Acad. Sci. USA 110: E4987-E4996.
23. + memory T cells. Nat. Commun. 5: 5407.
24. Karn, J. 2011. The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr. Opin. HIV AIDS 6: 4-11.
25. Taube, R., and M. Peterlin. 2013. Lost in transcription: molecular mechanisms that control HIV latency. Viruses 5: 902-927.
26. Ruelas, D. S., and W. C. Greene. 2013. An integrated overview of HIV-1 latency. Cell 155: 519-529.
27. Dahabieh, M. S., E. Battivelli, and E. Verdin. 2015. Understanding HIV latency: the road to an HIV cure. Annu. Rev. Med. 66: 407-421.
28. Spivak, A. M., and V. Planelles. 2016. HIV-1 eradication: early trials (and tribulations). Trends Mol. Med. 22: 10-27.
29. Archin, N. M., J. M. Sung, C. Garrido, N. Soriano-Sarabia, and D. M. Margolis. 2014. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12: 750-764.
30. Katlama, C., S. G. Deeks, B. Autran, J. Martinez-Picado, J. van Lunzen, C. Rouzioux, M. Miller, S. Vella, J. E. Schmitz, J. Ahlers, et al. 2013. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381: 2109-2117.
31. Speck, S. H., and D. Ganem. 2010. Viral latency and its regulation: lessons from the g-herpesviruses. Cell Host Microbe 8: 100-115.
32. Perng, G. C., and C. Jones. 2010. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. Interdiscip. Perspect. Infect. Dis. 2010: 262415.
33. Piatak, M., Jr., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754.
34. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: 205-211.
35. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
36. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100: 4144-4149.
37. Leslie, A. J., K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes, T. Allen, J. G. Prado, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10: 282-289.
38. Jones, N. A., X. Wei, D. R. Flower, M. Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow. 2004. Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200: 1243-1256.
39. Frost, S. D., T. Wrin, D. M. Smith, S. L. Kosakovsky Pond, Y. Liu, E. Paxinos, C. Chappey, J. Galovich, J. Beauchaine, C. J. Petropoulos, et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102: 18514-18519.
40. Wood, N., T. Bhattacharya, B. F. Keele, E. Giorgi, M. Liu, B. Gaschen, M. Daniels, G. Ferrari, B. F. Haynes, A. McMichael, et al. 2009. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 5: e1000414.
41. Deng, K., M. Pertea, A. Rongvaux, L. Wang, C. M. Durand, G. Ghiaur, J. Lai, H. L. McHugh, H. Hao, H. Zhang, et al. 2015. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517: 381-385.
42. + T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95: 8869-8873.
43. Buckheit, R. W., III, M. Salgado, K. O. Martins, and J. N. Blankson. 2013. The implications of viral reservoirs on the elite control of HIV-1 infection. Cell. Mol. Life Sci. 70: 1009-1019.
44. Persaud, D., H. Gay, C. Ziemniak, Y. H. Chen, M. Piatak, Jr., T. W. Chun, M. Strain, D. Richman, and K. Luzuriaga. 2013. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369: 1828-1835.
45. + T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J. Virol. 77: 4938-4949.
46. Dinoso, J. B., S. A. Rabi, J. N. Blankson, L. Gama, J. L. Mankowski, R. F. Siliciano, M. C. Zink, and J. E. Clements. 2009. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 83: 9247-9257.
47. Whitney, J. B., A. L. Hill, S. Sanisetty, P. Penaloza-MacMaster, J. Liu, M. Shetty, L. Parenteau, C. Cabral, J. Shields, S. Blackmore, et al. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512: 74-77.
48. Rouzine, I. M., A. D. Weinberger, and L. S. Weinberger. 2015. An evolutionary role for HIV latency in enhancing viral transmission. Cell 160: 1002-1012.
49. Razooky, B. S., A. Pai, K. Aull, I. M. Rouzine, and L. S. Weinberger. 2015. A hardwired HIV latency program. Cell 160: 990-1001.
50. Margolick, J. B., D. J. Volkman, T. M. Folks, and A. S. Fauci. 1987. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J. Immunol. 138: 1719-1723.
51. + T cells. Science 286: 1353-1357.
52. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, et al. 1996. Identification of a major coreceptor for primary isolates of HIV-1. Nature 381: 661-666.
53. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
54. Wu, L., N. P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A. A. Cardoso, E. Desjardin, W. Newman, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183.
55. Trkola, A., T. Dragic, J. Arthos, J. M. Binley, W. C. Olson, G. P. Allaway, C. Cheng-Mayer, J. Robinson, P. J. Maddon, and J. P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384: 184-187.
56. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, et al. 1996. The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148.
57. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
58. Bleul, C. C., L. Wu, J. A. Hoxie, T. A. Springer, and C. R. Mackay. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94: 1925-1930.
59. Mohammadi, P., S. Desfarges, I. Bartha, B. Joos, N. Zangger, M. Muñoz, H. F. Gunthard, N. Beerenwinkel, A. Telenti, and A. Ciuffi. 2013. 24 hours in the life of HIV-1 in a T cell line. PLoS Pathog. 9: e1003161.
60. Nabel, G., and D. Baltimore. 1987. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713.
61. Böhnlein, E., J. W. Lowenthal, M. Siekevitz, D. W. Ballard, B. R. Franza, and W. C. Greene. 1988. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-a gene and type 1 HIV. Cell 53: 827-836.
62. Duh, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, and A. B. Rabson. 1989. Tumor necrosis factor a activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kB sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86: 5974-5978.
63. Adams, M., L. Sharmeen, J. Kimpton, J. M. Romeo, J. V. Garcia, B. M. Peterlin, M. Groudine, and M. Emerman. 1994. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc. Natl. Acad. Sci. USA 91: 3862-3866.
64. Kinoshita, S., B. K. Chen, H. Kaneshima, and G. P. Nolan. 1998. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 95: 595-604.
65. + T lymphocytes and macrophages. Curr. HIV Res. 1: 395-404.
66. Lin, X., D. Irwin, S. Kanazawa, L. Huang, J. Romeo, T. S. Yen, and B. M. Peterlin. 2003. Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir. J. Virol. 77: 8227-8236.
67. Pessler, F., and R. Q. Cron. 2004. Reciprocal regulation of the nuclear factor of activated T cells and HIV-1. Genes Immun. 5: 158-167.
68. Laguette, N., B. Sobhian, N. Casartelli, M. Ringeard, C. Chable-Bessia, E. Ségéral, A. Yatim, S. Emiliani, O. Schwartz, and M. Benkirane. 2011. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
69. Berger, A., A. F. Sommer, J. Zwarg, M. Hamdorf, K. Welzel, N. Esly, S. Panitz, A. Reuter, I. Ramos, A. Jatiani, et al. 2011. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7: e1002425.
70. + T cells. Nat. Med. 18: 1682-1687.
71. Romani, B., and E. A. Cohen. 2012. Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr. Opin. Virol. 2: 755-763.
72. Zack, J. A., S. J. Arrigo, S. R. Weitsman, A. S. Go, A. Haislip, and I. S. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61: 213-222.
73. Pierson, T. C., Y. Zhou, T. L. Kieffer, C. T. Ruff, C. Buck, and R. F. Siliciano. 2002. Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J. Virol. 76: 8518-8531.
74. + T cell activation to c-Myc-dependent deoxyribonucleotide pool expansion and HIV-1 replication. PLoS Pathog. 11: e1004864.
75. Yoder, A., D. Yu, L. Dong, S. R. Iyer, X. Xu, J. Kelly, J. Liu, W. Wang, P. J. Vorster, L. Agulto, et al. 2008. HIV envelope-CXCR4 signaling activates cofilin to overcome cortical actin restriction in resting CD4 T cells. Cell 134: 782-792.
76. Doitsh, G., N. L. Galloway, X. Geng, Z. Yang, K. M. Monroe, O. Zepeda, P. W. Hunt, H. Hatano, S. Sowinski, I. Muñoz-Arias, and W. C. Greene. 2014. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505: 509-514.
77. Monroe, K. M., Z. Yang, J. R. Johnson, X. Geng, G. Doitsh, N. J. Krogan, and W. C. Greene. 2014. IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV. Science 343: 428-432.
78. Muñoz-Arias, I., G. Doitsh, Z. Yang, S. Sowinski, D. Ruelas, and W. C. Greene. 2015. Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection. Cell Host Microbe 18: 463-470.
79. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
80. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
81. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
82. Ahmed, R., and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272: 54-60.
83. Sakai, K., J. Dimas, and M. J. Lenardo. 2006. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl. Acad. Sci. USA 103: 3369-3374.
84. Cooper, A., M. Garc?a, C. Petrovas, T. Yamamoto, R. A. Koup, and G. J. Nabel. 2013. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 498: 376-379.
85. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIVspecific cytotoxic T lymphocytes in seropositive individuals. Nature 328: 345-348.
86. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
87. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
88. Wong, J. K., M. C. Strain, R. Porrata, E. Reay, S. Sankaran-Walters, C. C. Ignacio, T. Russell, S. K. Pillai, D. J. Looney, and S. Dandekar. 2010. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLoS Pathog. 6: e1000748.
89. Klatt, N. R., E. Shudo, A. M. Ortiz, J. C. Engram, M. Paiardini, B. Lawson, M. D. Miller, J. Else, I. Pandrea, J. D. Estes, et al. 2010. CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog. 6: e1000747.
90. He, G., L. Ylisastigui, and D. M. Margolis. 2002. The regulation of HIV-1 gene expression: the emerging role of chromatin. DNA Cell Biol. 21: 697-705.
91. Ylisastigui, L., N. M. Archin, G. Lehrman, R. J. Bosch, and D. M. Margolis. 2004. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18: 1101-1108.
92. West, M. J., A. D. Lowe, and J. Karn. 2001. Activation of human immunodeficiency virus transcription in T cells revisited: NF-kB p65 stimulates transcriptional elongation. J. Virol. 75: 8524-8537.
93. Dornadula, G., H. Zhang, B. VanUitert, J. Stern, L. Livornese, Jr., M. J. Ingerman, J. Witek, R. J. Kedanis, J. Natkin, J. DeSimone, and R. J. Pomerantz. 1999. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282: 1627-1632.
94. Palmer, S., A. P. Wiegand, F. Maldarelli, H. Bazmi, J. M. Mican, M. Polis, R. L. Dewar, A. Planta, S. Liu, J. A. Metcalf, et al. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41: 4531-4536.
95. Maldarelli, F., S. Palmer, M. S. King, A. Wiegand, M. A. Polis, J. Mican, J. A. Kovacs, R. T. Davey, D. Rock-Kress, R. Dewar, et al. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3: e46.
96. Hermankova, M., S. C. Ray, C. Ruff, M. Powell-Davis, R. Ingersoll, R. T. D'Aquila, T. C. Quinn, J. D. Siliciano, R. F. Siliciano, and D. Persaud. 2001. HIV-1 drug resistance profiles in children and adults with viral load of ,50 copies/ml receiving combination therapy. JAMA 286: 196-207.
97. Kieffer, T. L., M. M. Finucane, R. E. Nettles, T. C. Quinn, K. W. Broman, S. C. Ray, D. Persaud, and R. F. Siliciano. 2004. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189: 1452-1465.
98. Persaud, D., G. K. Siberry, A. Ahonkhai, J. Kajdas, D. Monie, N. Hutton, D. C. Watson, T. C. Quinn, S. C. Ray, and R. F. Siliciano. 2004. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J. Virol. 78: 968-979.
99. Nettles, R. E., T. L. Kieffer, P. Kwon, D. Monie, Y. Han, T. Parsons, J. Cofrancesco, Jr., J. E. Gallant, T. C. Quinn, B. Jackson, et al. 2005. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
100. + T cells. J. Virol. 80: 6441-6457.
101. Nickle, D. C., M. A. Jensen, D. Shriner, S. J. Brodie, L. M. Frenkel, J. E. Mittler, and J. I. Mullins. 2003. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J. Virol. 77: 5540-5546.
102. Tobin, N. H., G. H. Learn, S. E. Holte, Y. Wang, A. J. Melvin, J. L. McKernan, D. M. Pawluk, K. M. Mohan, P. F. Lewis, J. I. Mullins, and L. M. Frenkel. 2005. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J. Virol. 79: 9625-9634.
103. Dinoso, J. B., S. Y. Kim, A. M. Wiegand, S. E. Palmer, S. J. Gange, L. Cranmer, A. O'Shea, M. Callender, A. Spivak, T. Brennan, et al. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 106: 9403-9408.
104. Gandhi, R. T., L. Zheng, R. J. Bosch, E. S. Chan, D. M. Margolis, S. Read, B. Kallungal, S. Palmer, K. Medvik, M. M. Lederman, et al; AIDS Clinical Trials Group A5244 team. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7: e1000321.
105. McMahon, D., J. Jones, A. Wiegand, S. J. Gange, M. Kearney, S. Palmer, S. McNulty, J. A. Metcalf, E. Acosta, C. Rehm, et al. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 50: 912-919.
106. Joos, B., M. Fischer, H. Kuster, S. K. Pillai, J. K. Wong, J. Böni, B. Hirschel, R. Weber, A. Trkola, and H. F. Gunthard, Swiss HIV Cohort Study. 2008. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc. Natl. Acad. Sci. USA 105: 16725-16730.
107. Hill, A. L., D. I. Rosenbloom, F. Fu, M. A. Nowak, and R. F. Siliciano. 2014. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc. Natl. Acad. Sci. USA 111: 13475-13480.
108. Eriksson, S., E. H. Graf, V. Dahl, M. C. Strain, S. A. Yukl, E. S. Lysenko, R. J. Bosch, J. Lai, S. Chioma, F. Emad, et al. 2013. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9: e1003174.
109. Hutter, G., D. Nowak, M. Mossner, S. Ganepola, A. Mussig, K. Allers, T. Schneider, J. Hofmann, C. Kucherer, O. Blau, et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360: 692-698.
110. Henrich, T. J., Z. Hu, J. Z. Li, G. Sciaranghella, M. P. Busch, S. M. Keating, S. Gallien, N. H. Lin, F. F. Giguel, L. Lavoie, et al. 2013. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J. Infect. Dis. 207: 1694-1702.
111. Henrich, T. J., E. Hanhauser, F. M. Marty, M. N. Sirignano, S. Keating, T. H. Lee, Y. P. Robles, B. T. Davis, J. Z. Li, A. Heisey, et al. 2014. Antiretroviralfree HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161: 319-327.
112. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233: 215-219.
113. Koenig, S., H. E. Gendelman, J. M. Orenstein, M. C. Dal Canto, G. H. Pezeshkpour, M. Yungbluth, F. Janotta, A. Aksamit, M. A. Martin, and A. S. Fauci. 1986. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093.
114. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc. Natl. Acad. Sci. USA 98: 658-663.
115. Babas, T., D. Muñoz, J. L. Mankowski, P. M. Tarwater, J. E. Clements, and M. C. Zink. 2003. Role of microglial cells in selective replication of simian immunodeficiency virus genotypes in the brain. J. Virol. 77: 208-216.
116. González-Scarano, F., and J. Mart?n-Garc?a. 2005. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 5: 69-81.
117. Peng, G., T. Greenwell-Wild, S. Nares, W. Jin, K. J. Lei, Z. G. Rangel, P. J. Munson, and S. M. Wahl. 2007. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110: 393-400.
118. Arfi, V., L. Rivière, L. Jarrosson-Wuillème, C. Goujon, D. Rigal, J. L. Darlix, and A. Cimarelli. 2008. Characterization of the early steps of infection of primary blood monocytes by human immunodeficiency virus type 1. J. Virol. 82: 6557-6565.
119. Schnell, G., S. Spudich, P. Harrington, R. W. Price, and R. Swanstrom. 2009. Compartmentalized human immunodeficiency virus type 1 originates from longlived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 5: e1000395.
120. + T lymphocytes. J. Leukoc. Biol. 87: 575-588.
121. Schnell, G., S. Joseph, S. Spudich, R. W. Price, and R. Swanstrom. 2011. HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog. 7: e1002286.
122. Cribbs, S. K., J. Lennox, A. M. Caliendo, L. A. Brown, and D. M. Guidot. 2015. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages. AIDS Res. Hum. Retroviruses 31: 64-70.
123. Honeycutt, J. B., A. Wahl, C. Baker, R. A. Spagnuolo, J. Foster, O. Zakharova, S. Wietgrefe, C. Caro-Vegas, V. Madden, G. Sharpe, et al. 2016. Macrophages sustain HIV replication in vivo independently of T cells. J. Clin. Invest. 126: 1353-1366.
124. Eisele, E., and R. F. Siliciano. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37: 377-388.
125. + T-lymphocytes. Virology 355: 127-137.
126. + T cells. Blood 113: 58-65.
127. Yang, H. C., S. Xing, L. Shan, K. O'Connell, J. Dinoso, A. Shen, Y. Zhou, C. K. Shrum, Y. Han, J. O. Liu, et al. 2009. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J. Clin. Invest. 119: 3473-3486.
128. + cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J. Virol. 84: 6425-6437.
129. + T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood 110: 4161-4164.
130. Kordelas, L., J. Verheyen, D. W. Beelen, P. A. Horn, A. Heinold, R. Kaiser, R. Trenschel, D. Schadendorf, U. Dittmer, and S. Esser, Essen HIV AlloSCT Group. 2014. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N. Engl. J. Med. 371: 880-882.
131. + T-cells carrying replicationcompetent virus in HIV-1-infected individuals. Methods Mol. Biol. 304: 3-15.
132. Laird, G. M., E. E. Eisele, S. A. Rabi, J. Lai, S. Chioma, J. N. Blankson, J. D. Siliciano, and R. F. Siliciano. 2013. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9: e1003398.
133. + T cells using a limiting dilution coculture assay. Methods Mol. Biol. 1354: 239-253.
134. Chun, T. W., D. C. Nickle, J. S. Justement, D. Large, A. Semerjian, M. E. Curlin, M. A. O'Shea, C. W. Hallahan, M. Daucher, D. J. Ward, et al. 2005. HIVinfected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115: 3250-3255.
135. Fletcher, C. V., K. Staskus, S. W. Wietgrefe, M. Rothenberger, C. Reilly, J. G. Chipman, G. J. Beilman, A. Khoruts, A. Thorkelson, T. E. Schmidt, et al. 2014. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl. Acad. Sci. USA 111: 2307-2312.
136. Lorenzo-Redondo, R., H. R. Fryer, T. Bedford, E. Y. Kim, J. Archer, S. L. Kosakovsky Pond, Y. S. Chung, S. Penugonda, J. G. Chipman, C. V. Fletcher, et al. 2016. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530: 51-56.
137. Martin, A. R., and R. F. Siliciano. 2016. Progress toward HIV eradication: case reports, current efforts, and the challenges associated with cure. Annu. Rev. Med. 67: 215-228.
138. Shankarappa, R., J. B. Margolick, S. J. Gange, A. G. Rodrigo, D. Upchurch, H. Farzadegan, P. Gupta, C. R. Rinaldo, G. H. Learn, X. He, et al. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73: 10489-10502.
139. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69: 5087-5094.
140. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
141. Yu, Q., R. König, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J. M. Coffin, and N. R. Landau. 2004. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11: 435-442.
142. + T cells in vivo. J. Virol. 79: 1975-1980.
143. Cuevas, J. M., R. Geller, R. Garijo, J. López-Aldeguer, and R. Sanjuán. 2015. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol. 13: e1002251.
144. Mens, H., A. G. Pedersen, L. B. Jørgensen, S. Hue, Y. Yang, J. Gerstoft, and T. L. Katzenstein. 2007. Investigating signs of recent evolution in the pool of proviral HIV type 1 DNA during years of successful HAART. AIDS Res. Hum. Retroviruses 23: 107-115.
145. Wagner, T. A., J. L. McKernan, N. H. Tobin, K. A. Tapia, J. I. Mullins, and L. M. Frenkel. 2013. An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J. Virol. 87: 1770-1778.
146. + T cells in acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 182: 1636-1642.
147. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
148. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
149. Gunthard, H. F., J. K. Wong, C. C. Ignacio, J. C. Guatelli, N. L. Riggs, D. V. Havlir, and D. D. Richman. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72: 2422-2428.
150. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15: 247-277.
151. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350: 1023-1035.
152. Theys, K., J. Snoeck, J. Vercauteren, A. B. Abecasis, A. M. Vandamme, and R. J. Camacho, Portuguese HIV-1 Resistance Study Group. 2013. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir. J. Antimicrob. Chemother. 68: 419-423.
153. Charpentier, C., S. Lambert-Niclot, B. Visseaux, L. Morand-Joubert, A. Storto, L. Larrouy, R. Landman, V. Calvez, A. G. Marcelin, and D. Descamps. 2013. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. J. Antimicrob. Chemother. 68: 2197-2198.
154. Bontell, I., A. Häggblom, G. Bratt, J. Albert, and A. Sönnerborg. 2013. Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011. PLoS One 8: e59337.
155. Nakagawa, F., M. May, and A. Phillips. 2013. Life expectancy living with HIV: recent estimates and future implications. Curr. Opin. Infect. Dis. 26: 17-25.
156. van Sighem, A. I., L. A. Gras, P. Reiss, K. Brinkman, and F. de Wolf, ATHENA national observational cohort study. 2010. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24: 1527-1535.
157. Mills, E. J., C. Bakanda, J. Birungi, K. Chan, N. Ford, C. L. Cooper, J. B. Nachega, M. Dybul, and R. S. Hogg. 2011. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann. Intern. Med. 155: 209-216.
158. Johnson, L. F., J. Mossong, R. E. Dorrington, M. Schomaker, C. J. Hoffmann, O. Keiser, M. P. Fox, R. Wood, H. Prozesky, J. Giddy, et al; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration. 2013. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med. 10: e1001418.
159. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9: 1131-1137.
160. Takaki, A., M. Wiese, G. Maertens, E. Depla, U. Seifert, A. Liebetrau, J. L. Miller, M. P. Manns, and B. Rehermann. 2000. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat. Med. 6: 578-582.
161. Michie, C. A., A. McLean, C. Alcock, and P. C. Beverley. 1992. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360: 264-265.
162. Mclean, A. R., and C. A. Michie. 1995. In vivo estimates of division and death rates of human T lymphocytes. Proc. Natl. Acad. Sci. USA 92: 3707-3711.
163. Hellerstein, M. K., R. A. Hoh, M. B. Hanley, D. Cesar, D. Lee, R. A. Neese, and J. M. McCune. 2003. Subpopulations of long-lived and short-lived T cells in advanced HIV-1 infection. J. Clin. Invest. 112: 956-966.
164. Vrisekoop, N., I. den Braber, A. B. de Boer, A. F. Ruiter, M. T. Ackermans, S. N. van der Crabben, E. H. Schrijver, G. Spierenburg, H. P. Sauerwein, M. D. Hazenberg, et al. 2008. Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc. Natl. Acad. Sci. USA 105: 6115-6120.
165. De Boer, R. J., and A. S. Perelson. 2013. Quantifying T lymphocyte turnover. J. Theor. Biol. 327: 45-87.
166. Jowett, J. B., V. Planelles, B. Poon, N. P. Shah, M. L. Chen, and I. S. Chen. 1995. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J. Virol. 69: 6304-6313.
167. Gérard, F. C., R. Yang, B. Romani, A. Poisson, J. P. Belzile, N. Rougeau, and E. A. Cohen. 2014. Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest. PLoS One 9: e89195.
168. Romani, B., N. Shaykh Baygloo, M. R. Aghasadeghi, and E. Allahbakhshi. 2015. HIV-1 Vpr protein enhances proteasomal degradation of MCM10 DNA replication factor through the Cul4-DDB1[VprBP] E3 ubiquitin ligase to induce G2/M cell cycle arrest. J. Biol. Chem. 290: 17380-17389.
169. + T cells. PLoS Pathog. 7: e1002288.
170. Maldarelli, F., X. Wu, L. Su, F. R. Simonetti, W. Shao, S. Hill, J. Spindler, A. L. Ferris, J. W. Mellors, M. F. Kearney, et al. 2014. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345: 179-183.
171. Wagner, T. A., S. McLaughlin, K. Garg, C. Y. Cheung, B. B. Larsen, S. Styrchak, H. C. Huang, P. T. Edlefsen, J. I. Mullins, and L. M. Frenkel. 2014. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345: 570-573.
172. + T cells can produce infectious HIV-1 in vivo. Proc. Natl. Acad. Sci. USA 113: 1883-1888.
173. Swain, S. L., H. Hu, and G. Huston. 1999. Class II-independent generation of CD4 memory T cells from effectors. Science 286: 1381-1383.
174. Kassiotis, G., S. Garcia, E. Simpson, and B. Stockinger. 2002. Impairment of immunological memory in the absence of MHC despite survival of memory T cells. Nat. Immunol. 3: 244-250.
175. + T cells in vivo. J. Virol. 80: 6801-6809.
176. + memory-phenotype T cells are abundant in unexposed adults. Immunity 38: 373-383.
177. Surh, C. D., and J. Sprent. 2008. Homeostasis of naive and memory T cells. Immunity 29: 848-862.
178. Maeurer, M. J., and M. T. Lotze. 1998. Interleukin-7 (IL-7) knockout mice. Implications for lymphopoiesis and organ-specific immunity. Int. Rev. Immunol. 16: 309-322.
179. + memory T cells are IL-15 dependent. J. Exp. Med. 204: 951-961.
180. Scripture-Adams, D. D., D. G. Brooks, Y. D. Korin, and J. A. Zack. 2002. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 76: 13077-13082.
181. Wang, F. X., Y. Xu, J. Sullivan, E. Souder, E. G. Argyris, E. A. Acheampong, J. Fisher, M. Sierra, M. M. Thomson, R. Najera, et al. 2005. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. 115: 128-137.
182. Vandergeeten, C., R. Fromentin, S. DaFonseca, M. B. Lawani, I. Sereti, M. M. Lederman, M. Ramgopal, J. P. Routy, R. P. Sékaly, and N. Chomont. 2013. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121: 4321-4329.
183. Katlama, C., S. Lambert-Niclot, L. Assoumou, L. Papagno, F. Lecardonnel, R. Zoorob, G. Tambussi, B. Clotet, M. Youle, C. J. Achenbach, et al; EraMune-01 study team. 2016. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 30: 221-230.
184. Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
185. + central memory T cells. J. Exp. Med. 204: 79-91.
186. + T cells. J. Virol. 88: 14070-14077.
187. Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. Almeida, E. Gostick, Z. Yu, C. Carpenito, et al. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17: 1290-1297.
188. + T cells with stem cell-like properties. Nat. Med. 20: 139-142.
189. Ho, Y. C., L. Shan, N. N. Hosmane, J. Wang, S. B. Laskey, D. I. Rosenbloom, J. Lai, J. N. Blankson, J. D. Siliciano, and R. F. Siliciano. 2013. Replicationcompetent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155: 540-551.
190. Reinhardt, R. L., A. Khoruts, R. Merica, T. Zell, and M. K. Jenkins. 2001. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410: 101-105.
191. Thome, J. J., N. Yudanin, Y. Ohmura, M. Kubota, B. Grinshpun, T. Sathaliyawala, T. Kato, H. Lerner, Y. Shen, and D. L. Farber. 2014. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell 159: 814-828.
192. Farber, D. L., N. A. Yudanin, and N. P. Restifo. 2014. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14: 24-35.
193. + T follicular helper, B, and CD8+ T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J. Immunol. 188: 3247-3256.
194. Perreau, M., A. L. Savoye, E. De Crignis, J. M. Corpataux, R. Cubas, E. K. Haddad, L. De Leval, C. Graziosi, and G. Pantaleo. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210: 143-156.
195. Connick, E., J. M. Folkvord, K. T. Lind, E. G. Rakasz, B. Miles, N. A. Wilson, M. L. Santiago, K. Schmitt, E. B. Stephens, H. O. Kim, et al. 2014. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. J. Immunol. 193: 5613-5625.
196. Fukazawa, Y., R. Lum, A. A. Okoye, H. Park, K. Matsuda, J. Y. Bae, S. I. Hagen, R. Shoemaker, C. Deleage, C. Lucero, et al. 2015. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21: 132-139.
197. Shan, L., K. Deng, N. S. Shroff, C. M. Durand, S. A. Rabi, H. C. Yang, H. Zhang, J. B. Margolick, J. N. Blankson, and R. F. Siliciano. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
198. Clark, R. A. 2015. Resident memory T cells in human health and disease. Sci. Transl. Med. 7: 269rv1.
199. Thome, J. J., and D. L. Farber. 2015. Emerging concepts in tissue-resident T cells: lessons from humans. Trends Immunol. 36: 428-435.
200. Purwar, R., J. Campbell, G. Murphy, W. G. Richards, R. A. Clark, and T. S. Kupper. 2011. Resident memory T cells (TRM) are abundant in human lung: diversity, function, and antigen specificity. PLoS One 6: e16245.
201. Chun, T. W., D. C. Nickle, J. S. Justement, J. H. Meyers, G. Roby, C. W. Hallahan, S. Kottilil, S. Moir, J. M. Mican, J. I. Mullins, et al. 2008. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197: 714-720.
202. Lerner, P., M. Guadalupe, R. Donovan, J. Hung, J. Flamm, T. Prindiville, S. Sankaran-Walters, M. Syvanen, J. K. Wong, M. D. George, and S. Dandekar. 2011. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J. Virol. 85: 4772-4782.
203. + T cells. J. Virol. 85: 5220-5223.
204. Schröder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
205. + T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J. Virol. 78: 6122-6133.
206. Berry, C. C., N. A. Gillet, A. Melamed, N. Gormley, C. R. Bangham, and F. D. Bushman. 2012. Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics 28: 755-762.
207. Cohn, L. B., I. T. Silva, T. Y. Oliveira, R. A. Rosales, E. H. Parrish, G. H. Learn, B. H. Hahn, J. L. Czartoski, M. J. McElrath, C. Lehmann, et al. 2015. HIV-1 integration landscape during latent and active infection. Cell 160: 420-432.
208. + T cell populations during effective highly active antiretroviral therapy. J. Infect. Dis. 195: 716-725.
209. + T cells determined by replication-incompetent integrated HIV-1 provirus. AIDS 28: 1091-1099.
210. + T cells can produce infectious HIV-1 in vivo. Proc. Natl. Acad. Sci. 113: 1883-1888.